Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea's Celltrion In Deal With U.S.-based Hospira For Biogeneric Sales; M&A Hinted At

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Celltrion inked an agreement with U.S.-based Hospira to collaborate on manufacturing and marketing Celltrion's eight biogeneric products in global markets including the U.S. and Europe

Related Content

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
Hospira Hinges Emerging Market Success On Scale And Differentiation
Singapore's Ion Investments Buys Another 10% Stake In Korea's Celltrion In Anticipation of 2012 Biosimilars Launch
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
Korea's Celltrion Gains Foothold in Europe; Wins Clinical Trial Approval from Latvia For Herceptin Biosimilar
Korea's Celltrion Gains European Foothold With Latvian Clinical Trial Approval For Herceptin Biosimilar
South Korea's Economy Minister Pledges Support for Local Biosimilar Companies
South Korea's Economy Minister Pledges Support For Local Biosimilar Companies
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts